The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab.

BACKGROUND Patients with colorectal cancer (CRC) with wild-type KRAS mutations are often treated with the endothelial growth factor receptor (EGFR) monoclonal antibody cetuximab. Despite the presence of a specific molecular target, most patients still do not derive benefit from this biological treatment. Our study explores the role of ephrin A2 (EphA2) receptor expression and of EGFR pathway mediators as predictors of cetuximab benefit. PATIENTS AND METHODS Formalin-fixed paraffin-embedded (FFPE) tumor biopsy samples from 226 cetuximab-treated patients with CRC were studied for mRNA expression of insulin growth factor binding protein 2 (IGFBP2), insulin growth factor receptor 1 (IGF1R), cMET, EphA2, human epidermal growth factor receptor 2 (HER2), HER3, and HER4 by means of TaqMan reverse-transcribed polymerase chain reaction (RT-PCR). RESULTS Of the 226 patients evaluable for exploratory analysis, 222 had complete data from follow-up visits. The univariate analysis revealed the following significant adverse prognostic factors for risk of death: high EphA2 mRNA levels (hazard ratio [HR], 1.61; P = .015), high HER2 mRNA levels (HR, 1.51; P = .045), and high IGF1R mRNA levels (HR, 1.56; P = .021). Low EphA2 tumor expression was significantly associated with objective response to cetuximab therapy. In multivariate analysis of a broad biomarker panel, factors with independent prognostic value included EphA2 mRNA levels (HR, 1.67; P = .029), high amphiregulin (AREG) mRNA levels in KRAS wild-type tumors (HR, 0.17; P < .0001), and high epiregulin (EREG) mRNA levels (HR, 0.38; P = .006). CONCLUSION High EphA2 receptor expression in CRC was associated with a worse outcome in patients treated with cetuximab-based therapy. Prospective validation in treated and control patients is required to dissect the predictive from prognostic role in advanced CRC.

[1]  S. Ashley,et al.  Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness. , 2004, Biochemical and biophysical research communications.

[2]  Elena B. Pasquale,et al.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond , 2010, Nature Reviews Cancer.

[3]  A. Sidawy,et al.  Role of insulin-like growth factor-I (IGF-I) receptor, IGF-I, and IGF binding protein-2 in human colorectal cancers. , 1998, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[4]  L. Mazzucchelli,et al.  HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients , 2013, British Journal of Cancer.

[5]  Alexander Hapfelmeier,et al.  Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines , 2012, Journal of Cancer Research and Clinical Oncology.

[6]  C. Lepage,et al.  Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population , 2006, The British journal of surgery.

[7]  G. Viale,et al.  Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. , 1995, Cancer research.

[8]  J. Vandesompele,et al.  Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Harari,et al.  Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members , 2008, Oncogene.

[10]  F. Huang,et al.  Correlation between Gene Expression of IGF-1R Pathway Markers and Cetuximab Benefit in Metastatic Colorectal Cancer , 2012, Clinical Cancer Research.

[11]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  K. Syrigos,et al.  STAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN. , 2011, Translational oncology.

[13]  E. Manseau,et al.  Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. , 1993, Cancer research.

[14]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[15]  A. D. Van den Abbeele,et al.  Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. , 2010, AJR. American journal of roentgenology.

[16]  A. Boyd,et al.  The role of Eph receptors and ephrin ligands in colorectal cancer , 2009, International journal of cancer.

[17]  D. Nikolov,et al.  Eph receptors and ephrins. , 2003, The international journal of biochemistry & cell biology.

[18]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[19]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[20]  A. Pozzi,et al.  Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo , 2002, Oncogene.

[21]  P. Jänne,et al.  Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients , 2008, British Journal of Cancer.

[22]  H. McLeod,et al.  Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. , 2002, European journal of cancer.

[23]  T. Cenci,et al.  Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? , 2011, Clinical colorectal cancer.

[24]  A. Boyd,et al.  Complex expression patterns of Eph receptor tyrosine kinases and their ephrin ligands in colorectal carcinogenesis. , 2012, European journal of cancer.

[25]  E. Maccaroni,et al.  Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[27]  A. Psyrri,et al.  Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas , 2006, BMC Cancer.

[28]  D. Cunningham,et al.  A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. , 1999, Seminars in oncology.

[29]  M. Kinch,et al.  Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. , 2002, Cancer research.

[30]  R. Berardi,et al.  The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. , 2011, The oncologist.

[31]  E. Van Cutsem,et al.  Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Tzardi,et al.  Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients , 2011, PloS one.

[33]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[34]  F. Penault-Llorca,et al.  Impact of EGFR expression on colorectal cancer patient prognosis and survival. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  Manuel Hidalgo,et al.  Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Berardi,et al.  Insulin‐like growth factor 1 expression correlates with clinical outcome in K‐RAS wild type colorectal cancer patients treated with cetuximab and irinotecan , 2010, International journal of cancer.

[37]  Jin Chen,et al.  EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. , 2005, Current cancer drug targets.

[38]  E. Espinosa,et al.  Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen and formalin-fixed, paraffin-embedded breast cancer tissues. , 2010, BioTechniques.

[39]  A. Benson,et al.  Epidemiology, disease Progression, and Economic Burden of Colorectal Cancer , 2007, Journal of managed care pharmacy : JMCP.

[40]  H. Kuwano,et al.  Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis. , 2004, Oncology Report.

[41]  H. Lenz,et al.  Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients , 2010, Clinical Cancer Research.

[42]  P. Gascón,et al.  Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: A GEMCAD study , 2011, Cancer biology & therapy.

[43]  S. Shak,et al.  Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer , 2011, British Journal of Cancer.

[44]  M. Dimopoulos,et al.  Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study , 2008, British Journal of Cancer.

[45]  H. Augustin,et al.  Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. , 2006, Experimental cell research.